Aortic root (AR) dimension (ARD) enlargement has been associated with aortic regurgitation, arteriosclerosis, hypertension, and hypertensive organ damage. 1 Dilated ARD is observed more frequently in hypertensive than in normotensive individuals, and its prevalence is higher in patients with complicated hypertension, supporting idea that it might be considered as another marker of target organ damage (TOD). 2 Different methods have been used to evaluate ARD based on ratiometric or allometric normalization for measures of body size. The allometric normalization for height, adjusted for age and sex, proposed by Deveraux et al. has been shown to be pathophysiologically consistent with hemodynamic stimuli thought to influence ARD. 3 Although left ventricular (LV) hypertrophy (LVH) is reported as a major correlate of dilated ARD in hypertensive subjects, independent of age, body size, and gender, 4 acquired dilatation of ARD results from multiple complex mechanisms. 5 In addition to the alterations of LV geometry and function, chronic pressure overload is thought to act as an important determinant of ARD dilatation. 4, 6, 7 Systemic and cardiac growth factors involved in cardiac remodeling might be also involved in dilated ARD. 2 In addition, mild-to-moderate aortic regurgitation secondary to aortic dilatation adds hemodynamic burden and can contribute to progression of abnormalities of LV structure and function 8 and progression of aortic dilatation. 9 Some issues remain unresolved on epidemiological scale: Can dilated ARD be considered an additional marker for cardiovascular (CV) events, independently of the often coexisting LVH?
and to assess whether dilated ARD is associated with incident CV events, independent of other markers of TOD.
METHODS

Study population
The CSN is an open registry collecting information from general practitioners and community hospitals in the 5 districts of the Campania Region, in Southern Italy. 10 General practitioners and community hospitals are networked with the Hypertension Research Center of the Federico II University Hospital in Naples, Italy. The database generation of CSN was approved by our institutional Ethic Committee, and signed informed consent was obtained from all participants. All hypertensive patients of the network were referred for baseline echocardiograms and carotid ultrasound to our Hypertension Research Center. Detailed characteristics of CSN population have been previously repeatedly reported. [11] [12] [13] From the CSN, we selected 8,573 hypertensive patients, aged ≥18 years, with available echocardiograms, without prevalent CV disease and atrial fibrillation, more than mild valvular heart disease, more than stage III Chronic Kidney Disease, and with normal ejection fraction (>50%).
Echocardiographic evaluation
Echocardiograms were recorded in our Hypertension Center on videotapes, using commercial machines and a standardized protocol, were digitally mastered and read off-line by 1 expert reader under the supervision of a senior faculty member, using dedicated work-stations (MediMatic, Genova, Italy). 14 Measurements were made according to the American Society of Echocardiography/European Society of Echocardiography (ASE/EAE) recommendations. 15 LV mass was estimated from a necropsy-validated formula and normalized for height in meters to the power of 2.7 (left ventricular mass index, LVMi). 16 LVH was defined as LVMi ≥50 g/m 2.7 in men and ≥47 g/m 2.7 in women. 17 LV diastolic dimension was normalized by height in meters. LV concentric geometry was defined as a relative wall thickness ≥0.43 for either genders. LV volumes were estimated from linear measures of LV diameters by the z-derived method 18 and used to compute ejection fraction and stroke volume. 19 ARD was measured in the parasternal long-axis view at the level of sinus of Valsalva in end-diastole, using the leading-edge to leading-edge method. 20 Based on findings in a large healthy reference population, 3 the individual predicted ARD (ARD p ) was obtained by a multiple linear regression based upon actual age, sex, and height:
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The z-score of ARD (ARD-z) was generated based on the difference between the observed ARD and ARD p, divided by the SD of the observed sex-specific ARD value. 5 Thus, a positive ARD-z indicates ARD larger, and a negative ARD-z indicates ARD smaller than expected. ARD-z exceeding the 75th percentile of the distribution (corresponding to 1 SD) was arbitrarily considered as AR dilatation ( Figure 1) . A second method was also used to define AR dilatation, by the ratiometric normalization of observed ARD for the linear measure of height (ARDh). Similar to the first approach, AR was considered dilated if above the 75th percentile of the sex-specific distribution of ARDh (>2.23 in men and 2.15 cm/m in women, respectively).
Finally, we used a third method, with AR ratio metrically normalized for body surface area (ARDb). With this approach, AR was considered dilated if above the 75th percentile of the sex-specific distribution (>1.98 in men and 2.01 in women, respectively).
Outcome
A first episode of CV event represents the primary end point of the present study. Composite fatal and nonfatal stroke or myocardial infarction, sudden cardiac death, heart failure requiring hospitalization, transient ischemic attack, myocardial revascularization, de novo angina, carotid stenting, and atrial fibrillation were adjudicated as primary CV end point. All prevalent and incident CV events were adjudicated by the Committee for Event Adjudication in the Hypertension Research Center. Adjudication was based on patients' history, contact with the reference general practitioner, and clinical records documenting the occurrence of CV event. 21 
Statistics
Data were analyzed using SPSS (version 21.0; SPSS, Chicago, IL) and expressed as mean ± 1 SD. The χ 2 distribution was used to compare categorical variables, with the Monte Carlo simulation to obtain exact P values. LVMi and the above measures of normalized ARD were also dichotomized to define LVH and AR dilatation. Analysis of variance was used to compare baseline characteristics of patients with or without AR dilatation.
As previously reported, 16, 22 to account for antihypertensive therapy during follow-up, single classes of medications were dichotomized according to their overall use during the individual follow-up, based on the frequency of prescriptions at the control visits during follow-up. All medications prescribed for more than 50% of control visits in an individual patient during follow-up were considered as covariates in the Cox analyses. 16, 22 We calculated hazard ratios and 95% confidence interval, by using Cox proportional hazard regression models, for ARD-z, ARDh, and ARDb as either categorical variables or continuous variable, adjusting for baseline age and sex.
The last Cox model was also used to analyze the hazard of ARD-z in patients without baseline LVH (n = 5,394).
The null hypothesis was rejected at a two-tailed α-value of ≤0.05.
RESULTS
According to our criteria, 2,132 patients (23%) exhibited high ARD-z, whereas 4,082 had high ARDh (48%) and 2,099 had high ARDb (25%). Table 1 displays that patients with high ARD-z were younger, most likely to be men and obese and with more altered lipid profile, higher systolic blood pressure (BP), greater prevalence of LVH and concentric geometry, and lower ejection fraction than patients with normal ARD-z (all P < 0.005). Clinical characteristics of patients with dilated ARD index for height and body surface area (BSA) are reported in Supplementary Tables 1.1  and 1 
.2).
During a median follow-up of 54 months (interquartile range 11-80), 334 CV events occurred. In univariate Cox regression analysis and after adjusting for age and sex, dilated ARD-z was associated with 45% increased risk of CV events (P < 0.0001), whereas ARDh and ARDb were not (Table 2) .
In multivariable Cox regression model, high ARD-z predicted a 36% increased rate of CV events (95% confidence interval: 1.07-1.71, P = 0.011), independently of significant effect of older age, male sex, initial systolic BP, LVH, and a protective effect of anti-renin-angiotensin system therapy during follow-up (Table 3 and Figure 2) . No other class of medication was associated with incident CV events, and, interestingly, in this Cox model, obesity, diabetes, and concentric LV geometry were not significantly associated with adverse outcome. Due to the limited numbers of CV events, analysis of specific end point has not been provided.
In the subgroup of patients without baseline LVH (n = 5,394), 160 primary CV end point occurred during follow-up. Running the same Cox model analysis confirmed that dilated ARD-z was independently associated with 66% greater chance of incident CV events (P < 0.004) independent of significant effect of age, obesity, and less anti-renin-angiotensin system therapy (Table 4 ). In Kaplan-Mayer analysis, having dilated ARD without LVH (ARD+/LVH−) confers higher CV risk compared with patients without dilated ARD and LVH (ARD−/LVH−) and comparable risk as having LVH (ARD−/LVH+; P < 0.005 vs. ARD−/LVH−, P = 0.102 vs. ARD−/LVH+, Figure 3 ).
DISCUSSION
In this analysis, we established criteria for assessment of dilated AR using different methods, including multivariable normalization and traditional ratiometric indexations, using prognostic effect as a sensitivity criterion. The cut-points for dilated ARD that we proposed were useful in this analysis to compare the methods with a type of indirect validation that was useful to define the practical utility, in addition to the physiologic consistency.
The method for identification of ARD dilatation by the z-score, generated by a multivariable model produced by large normal reference population, could be successfully applied to a population of treated hypertensive patients, in a real-world outpatient setting. 3 This criterion of normalization of AR was the only one that could predict incident CV events, independent of confounders, also including LVH, the hallmark of markers of CV risk. The effect on prognosis of ARD dilatation was also confirmed in patients without baseline LVH, strongly indicating that the observed ARD larger than the size, which is ideally predicted by sex, body size, and age, expresses CV burden in patients with arterial hypertension and should be considered as another marker of TOD.
In a population with higher prevalence of obesity, indexation of ARD for BSA can lead to underdiagnosis of dilated ARD, influencing the ability to discriminate high CV risk, as well as indexation for height may not clearly take into account one main biological determinant of ARD such as age. 1 Interestingly, ratiometric normalization of ARD for height or BSA did not result in any prognostic valid classification of ARD. The simple ratiometric indexation for body size is not sufficient to give the right distribution of changes that the AR withstands due primarily to age and sex, in addition to body size, but also to the hemodynamic determinants highlighted in our previous work in the Strong Heart Study. 5 In addition, while with the linear measure of height the ratiometric approach is acceptable for geometric consistency, the one with BSA is not, due to the different geometric shape of the 2 parameters.
The prevalence of dilated ARD found in our study was higher compared with what has been found in previous epidemiological studies. 8, 23, 24 This apparent inconsistency may be explained also by the high CV risk profile of hypertensive patients referred our tertiary health care center, in addition to the better accuracy of ARD dilatation prediction based on its main biological determinants. 3, 25 Dilated ARD has been associated with cardiac and vascular TOD in hypertensive patients, in both population-based studies and clinical trials, 7, 8, 24 in accordance with our study and giving partial pathophysiological explanation for the increase CV risk related to dilated ARD.
In the PAMELA study, a general population-based study, ARD normalized for height, but not absolute ARD or ARD normalized for BSA, stratified the risk of future CV events. 4 Compare with our study population, prevalence of CV risk factors were substantially lower with less prevalent hypertension, diabetes, and obesity, despite higher incident CV events. In the Cardiovascular Health Study (CHS), crude measurement of ARD was associated with subclinical CV disease and predicted incident CV events. 26 Despite CHS was limited to old patients, there was a strong relation among age, CV risk factors, and ARD, strongly suggesting that evaluation of ARD should be always done taking into Abbreviations: ARDb, aortic root dimension indexed for BSA; ARDh, aortic root dimension indexed for height; ARD-z, aortic root dimension-z-score; CI, confidence interval; CV, cardiovascular; HR, hazard ratio. Abbreviations: ARD-z, aortic root dimension-z-score; BP, blood pressure; CI, confidence interval; CV, cardiovascular; HR, hazard ratio; LV, left ventricular; LVH, left ventricular hypertrophy; RAS, renin-angiotensin system. account its potential biological determinates. 27 In a Chinese community, patients <65 years in the highest tertiles of ARD normalized for BSA had increased risk of all-cause of death but not CV mortality. 28 At a younger age, the burden imposed on AR (i.e., diastolic hypertension, obesity) is more relevant, whereas in elderly hypertensive subjects, at a time when the organ damage is more consolidated, other factors take place to explain the association of AR dilatation with prognosis. This interpretation would be supported by the fact that despite AR dilatation is associated with younger age in exploratory analyses, aging maintains an independent impact on CV morbidity in the multivariable proportional hazard model.
The remodeling of the AR may be expected to occur in hypertensive subjects as a consequence of increased stress on the aortic wall due to the repeated hemodynamic overload, reflecting the parallel magnitude of increased LVM. 29 Data from the Framingham Heart Study clearly demonstrated parallel magnitude of increased ARD and LV mass suggesting a concomitant arterial-ventricular remodeling that contributes significantly to the development of heart failure after a follow-up of 8 years. 30 This wide evidence is in line with our findings, although the strong relationship of dilated ARD with CV outcome in patients without LVH suggests that the dilatation of AR could even proceed or being independent of the development of Abbreviations: ARD-z, aortic root dimension-z-score; BP, blood pressure; CI, confidence interval; CV, cardiovascular; HR, hazard ratio; RAS, renin-angiotensin system. LVH, suggesting closer follow-up for patients with dilated AR but not overt LVH.
Excluding patients with baseline LVH highlights the importance of obesity as a prognostic markers in hypertension, probably as a main determinant of development of LVH, 31 but did not alter the prognostic impact of dilated ARD suggesting different pathophysiological mechanism in the development of subsequent CV events, probably not simply mediated by BP values.
It is of interest to notice that both in the total study population and in the subgroup without baseline LVH, older age is always a main determinant of CV outcome. This aspect suggests that the CV remodeling that involves also the ARD in hypertensive patients affects CV prognosis mainly by aging, further underlining how important is to include the age as main determinant not only for AR remodeling but also for the complete CV profile.
Our study demonstrates that ARD dilatation is a marker of TOD, associated with increased incidence of CV events, independent of hypertensive LVH.
Study limitations
Our analysis has been performed in the setting of an observational registry in which observational bias cannot be excluded, despite the effort to include all patients seen in the recruitment centers.
Due to the low number of CV events, a subgroup analysis for single CV end point could not be run, and future studies are needed to assess the prognostic impact of dilated ARD on different CV end point.
Due to the observational nature of our study, direct-cause relationship cannot be ascertained, but our analysis may be used to generate new hypotheses on evolution toward clinically overt CV disease. 
